Publication | Open Access
Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
45
Citations
29
References
2023
Year
This study was sponsored by Betta Pharmaceutical Co., Ltd.
| Year | Citations | |
|---|---|---|
Page 1
Page 1